Pfizers monthly obesity injection drove shows promise in trial Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial The data offer early evidence that the
Clinical Trial for Obesity and Overweight. | Pfizer This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D
Study Details | NCT06717425 | A Study to Learn About the Study Medicine . . . A research study involving human volunteers (also called participants) that is intended to add to medical knowledge There are two types of clinical studies: interventional studies (also called clinical trials) and observational studies
Pfizer dips on new data for obesity drug acquired in $10B deal An experimental obesity shot Pfizer got through a buyout of Metsera helped enrollees in a mid-stage trial lose significantly more weight than a placebo, spurring up to an 11% reduction over 28 weeks using a regimen that switched from a weekly to monthly dose after 12 weeks
Pfizer Phase IIb Data Support Monthly GLP-1 Dosing for Obesity Pfizer plans a broad Phase III development program for PF-08653944, including trials for populations with and without type 2 diabetes The VESPER-3 trial results show that extended-interval GLP-1 dosing may expand obesity care by balancing sustained weight loss with reduced injection burden
Calendario